Abstract: Objective To explore the clinical efficacy and safety of CTguided radiofrequency ablation plus intratumoral chemotherapy in patients with stage Ⅲ nonsmall cell lung cancer (NSCLC). MethodsFrom February 2014 to May 2015, 38 patients with stage Ⅲ NSCLC who did not receive systematic chemotherapy due to advanced age were selected in our hospital. The patients were divided into experimental group (n=19) and control group (n=19) by stratified random method. The patients in experimental group received CTguided radiofrequency ablation plus Lobaplatin intratumoral chemotherapy, and the patients in control group only received CTguided radiofrequency ablation. The adverse events, Karnofsky performance system (KPS) scores, 1year overall survival rates and shortterm curative effects of patients in the two groups were observed. ResultsAll 38 patients completed the course of therapy successfully. The 3month response rates and 6month response rates in experimental group and control group were 89.5% vs. 63.2% and 78.9% vs. 52.6%, with no significant differences (P=0.124； P=0.170). The KPS score improvement rates were 42.1% (8/19) and 31.6% (6/19) in experimental group and control group, the KPS score stable rates were 52.6% (10/19) and 52.6% (10/19) in the two groups, and the KPS score deterioration rates were 5.3% (1/19) and 15.8% (3/19) in the two groups, with no significant differences (P=0.737; P=1.000; P=0.290). The 1year survival rate of patients in experimental group was higher than that in control group (89.5% vs. 73.7%), with a significant difference (χ2=5.573, P=0.034). The rates of less than or equal to grade 3 pain (31.6% vs. 42.1%), low fever (21.1% vs. 26.3%), aerothorax (31.6% vs. 42.1%), gastrointestinal reaction (15.8% vs. 31.6%) and bone marrow depression (5.3% vs. 15.8%) in experimental group were lower than those in control group, but the differences were not statistically significant (P=0.501; P=0.703; P=0.501; P=0.252; P=0.290). ConclusionCTguided radiofrequency ablation plus intratumoral chemotherapy for stage Ⅲ NSCLC can improve shortterm survival rate, and it does not increase the adverse reaction. While, the longterm overall survival rate has yet to be followed up.【Key words】

Key words: Carcinoma, non-small-cell lung, Catheter ablation, Lobaplatin, Intratumoral chemotherapy